Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate
- PMID: 11746276
- DOI: 10.1002/pros.10025
Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate
Abstract
Background: Prostate cells secrete many molecules capable of regulating angiogenesis; however, which of these actually function as essential regulators of neovascularization is not yet clear.
Methods: Functional angiogenic mediators secreted by normal and diseased prostate cells were identified using an in vitro angiogenesis assay. These factors were quantified by immunoblot or ELISA and localized in tissue by immunohistochemistry.
Results: Normal prostate epithelial cell secretions were anti-angiogenic due to inhibitory thrombospondin-1 (TSP-1) whereas this inhibitor was decreased in the pro-angiogenic secretions derived from benign prostatic hyperplasia (BPH) and cancer cells. This pro-angiogenic activity depended primarily on fibroblast growth factor-2 (FGF-2) and/or vascular endothelial growth factor (VEGF) whose secretion was increased. Immunolocalization studies confirmed that the changes detected in vitro also occurred in vivo.
Conclusions: During disease progression in the prostate, production of TSP-1, the major inhibitor, is down-regulated while that of stimulatory FGF-2 and/or VEGF rise, leading to the induction of the new vessels necessary to support tumor growth.
Copyright 2001 Wiley-Liss, Inc.
Similar articles
-
Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.BJU Int. 2002 Feb;89(3):303-9. doi: 10.1046/j.1464-4096.2001.01417.x. BJU Int. 2002. PMID: 11856116
-
Molecular mediators of angiogenesis in bladder cancer.Cancer Res. 1998 Mar 15;58(6):1298-304. Cancer Res. 1998. PMID: 9515819
-
The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.J Urol. 2001 Jun;165(6 Pt 1):2075-81. doi: 10.1097/00005392-200106000-00073. J Urol. 2001. PMID: 11371931
-
Clinical significance of the determination of angiogenic factors.Eur J Cancer. 1996 Dec;32A(14):2513-9. doi: 10.1016/s0959-8049(96)00397-8. Eur J Cancer. 1996. PMID: 9059341 Review. No abstract available.
-
Tumor angiogenesis.J Investig Dermatol Symp Proc. 2000 Dec;5(1):20-3. doi: 10.1046/j.1087-0024.2000.00003.x. J Investig Dermatol Symp Proc. 2000. PMID: 11147670 Review.
Cited by
-
Angiogenesis Inhibition in Prostate Cancer: An Update.Cancers (Basel). 2020 Aug 23;12(9):2382. doi: 10.3390/cancers12092382. Cancers (Basel). 2020. PMID: 32842503 Free PMC article. Review.
-
Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA.Mol Cancer. 2003 Oct 8;2:34. doi: 10.1186/1476-4598-2-34. Mol Cancer. 2003. PMID: 14613585 Free PMC article.
-
Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.BMC Cancer. 2010 Oct 30;10:596. doi: 10.1186/1471-2407-10-596. BMC Cancer. 2010. PMID: 21034500 Free PMC article.
-
Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis.Br J Cancer. 2002 May 6;86(9):1465-71. doi: 10.1038/sj.bjc.6600281. Br J Cancer. 2002. PMID: 11986782 Free PMC article.
-
Angiogenesis as Therapeutic Target in Metastatic Prostate Cancer - Narrowing the Gap Between Bench and Bedside.Front Immunol. 2022 Feb 10;13:842038. doi: 10.3389/fimmu.2022.842038. eCollection 2022. Front Immunol. 2022. PMID: 35222436 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous